HLA-DR

Product List

Here are the HLA-DR CAR products we offer you, including HLA-DR CAR vector products, CAR cell products, CAR mRNA.

Background

HLA-DR is a major histocompatibility complex (MHC) molecule of human class II containing two subunits (a and β). It is constitutively expressed on the surface of monocytes, macrophages, and B lymphocytes and presents antigens to CD4+ T cells. Most T cells do not express HLA-DR, and only a subset of activated T cells express HLA-DR during the later stages of the T cell response to the immune response. HLA-DR is co-expressed with CD1a in epidermal Langerhans cells.

HLA-DR is used for the enumeration of B lymphocytes and monocytes in peripheral blood; identification of lymphoma and leukemia; Expression of HLA-DR antigen on activated T lymphocytes and dendritic cell subsets in peripheral blood and lymphoid tissues.

Fig.1 Schematic diagram of DR and binding ligand (yellow). (Wikipedia)

Associated Diseases

Lymphoma

Acute B-lymphoblastic Leukemia

T-lymphocytic leukemia

Acute Myeloid Leukemia

Anti-HLA-DR CAR-T Services

HLA-DR CAR Design & Construction

Creative Biolabs focuses on the research and product development of tumor immunotherapy, providing design, customization and development services for HLA-DR CAR-T cells. Figure 1 shows a second-generation CAR construct designed using an anti-HLA-DR antibody.

Fig.2 Schematic diagram of the design of the HLA-DR (MVR) CAR.¹

Anti-HLA-DR CAR-T In Vitro Assays

Anti-HLA-DR CAR-T Expression Test

Based on years of technical experience, Creative Biolabs has developed unique fluorescently site-directed tagged protein products to facilitate the development of cell therapies. Figure 2 shows the flow cytometry results of CAR expression levels on the surface of HLA-DR CAR T cells.

Fig.3 Flow cytometry was used to analyze the expression of HLA-DR.¹

Anti-HLA-DR CAR-T Viability Study

The limited replicational lifespan of CAR-T cells is a major obstacle associated with current CAR-T cell therapy. Therefore, the viability and bio-distribution studies of CAR-T are of great significance for the development of CAR-T therapies. As a leading provider in the field of CAR-T development, Creative Biolabs now provides customers with testing services including in vivo proliferation, survival, migration and distribution of T cells, and T cell persistence.

Fig.4 Growth and viability of HLA-DR CAR.¹

Anti-HLA-DR CAR-T In Vitro Cytotoxicity Assay

In addition to providing cytokine release to measure CAR-T cell activity, Creative Biolabs also assesses the killing activity of CAR-T cells by assays of specific cell lysis in targeted tumor cell populations.

Fig.5 Cytotoxicity assay of HLA-DR CAR T cells.¹

Anti-HLA-DR CAR-T In Vivo Assays

Anti-HLA-DR CAR-T Cell Therapy Animal Models

Creative Biolabs offers xenograft models to evaluate in vivo HLA-DR CAR T cell efficacy. The figure below shows the flowchart of an in vivo study of HLA-DR CAR T cells in a xenograft mouse model.

Fig.6 HLA-DR CAR T cells in vivo evaluation procedure.¹

Efficacy Test of Anti-HLA-DR CAR-T

Creative Biolabs is committed to the development of tumor immunotherapy technology and has established a complete set of CAR-T in vivo pharmacodynamics experimental platforms to provide technical support and professional CAR-T services for CAR-T in vivo experiments. Figure 7 shows in vivo imaging of HLA-DR CAR T cells in a mouse model.

Fig.7 Tumor burden detection in transplanted mice.¹

Anti-HLA-DR CAR-T Cytokine Release Test

CAR-T cell quality testing mainly includes biochemical testing, microbial testing and cytology testing. Cytokine ELISA assays and flow cytometry are important ways to measure their activity and components.

Fig.8 IFN-γ levels following in vivo infusion of HLA-DR CAR T cells.¹

Reference

1. Han, Chungyong.; et al. "Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression." Nature communications. (2018) 9,1 468.